Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.7.48 (
transcriptase
)
9,479
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Insulin-like growth factor binding protein-3 (IGFBP-3) is known to induce apoptosis in an insulin-like growth factor (IGF)-dependent and IGF-independent manner, but the mechanism underlying the IGF-independent effects remains unclear. Polypeptide N-acetylgalactosaminyltransferase 14 (
GalNAc-T14
) is a novel IGFBP-3 binding partner. In this paper, small interference RNA (siRNA) targeting
GalNAc-T14
was used to examine whether
GalNAc-T14
affects the apoptotic action of IGFBP-3. Using semi-quantitative reverse-
transcriptase
polymerase chain reaction (RT-PCR) and western blot analysis, we determined that
GalNAc-T14
expression was downregulated by the siRNA directed against
GalNAc-T14
. Apoptosis analysis of IGFBP-3-overexpressing cells treated with siRNA against
GalNAc-T14
was performed to determine if
GalNAc-T14
was specifically involved in IGFBP-3 signalling. The results, as determined by flow cytometric analysis and caspase-3 assay, showed that the extent of apoptosis induced by IGFBP-increased with RNA interference (RNAi) knockdown of
GalNAc-T14
. Our data suggest that
GalNAc-T14
influences the apoptotic action of IGFBP-3 and might mediate the signalling pathway of IGFBP-3. Experiments to determine the role of
GalNAc-T14
in the regulation of apoptosis induced by IGFBP-3 are under way.
...
PMID:GalNAc-T14 may be involved in regulating the apoptotic action of IGFBP-3. 1980